{"id":497055,"date":"2026-08-07T00:00:00","date_gmt":"2026-08-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0014-2025-biopharma-immunoglobulin-a-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-08-19T11:20:23","modified_gmt":"2026-08-19T11:20:23","slug":"dlsfmd0014-2026-biopharma-immunoglobulin-a-nephropathy-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0014-2026-biopharma-immunoglobulin-a-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Immunoglobulin A Nephropathy &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Growing momentum across both established and emerging therapies is reshaping the <abbr title=\"immunoglobulin A\">IgA<\/abbr> nephropathy market as physicians balance established use of <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> and <abbr title=\"sodium-glucose co-transporter\">SGLT<\/abbr>2 inhibitors with adoption of newer therapies such as Asahi Kasei\u2019s Tarpeyo \/ Kinpeygo, Travere Therapeutics\u2019 Filspari, Novartis\u2019s Fabhalta and Vanrafia, and Otsuka Pharmaceuticals\u2019 Voyxact. Rising activity across late-phase programs, such as Alexion\u2019s ravulizumab, Roche\u2019s sefaxersen, Novartis\u2019s zigakibart, Vera Therapeutics\u2019 atacicept, Vertex\u2019s povetacicept, Biogen\u2019s felzartamab, and Takeda\u2019s mezagitamab, is increasing competitive pressure and prompting reassessment of longterm treatment planning. With multiple modalities advancing and additional launches expected within the next 10 years, nephrologists are reevaluating sequencing strategies, durability expectations, and patient allocation. Supported by insights from thought-leading nephrologists, we analyze the challenges and opportunities associated with treating this complex disease.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do physicians use current therapies to treat the disease?<\/li>\n<li>Where will Tarpeyo \/ Kinpeygo, Filspari, Fabhalta, Vanrafia, and Voyxact be positioned in the <abbr data-abbreviation-entity=\"10737\" title=\"immunoglobulin A\">IgA<\/abbr> nephropathy treatment landscape? Which emerging therapies do experts find most promising, and how will these drugs influence future prescribing patterns?<\/li>\n<li>What access and reimbursement challenges will emerging therapies face upon market entry?<\/li>\n<li>What key drivers and constraints will affect the <abbr title=\"immunoglobulin A\">IgA<\/abbr> nephropathy market over the forecast period?<\/li>\n<\/ul>\n<p><b>CONTENT HIGHLIGHTS<\/b><\/p>\n<ul class=\"round-bullets\">\n<li><b>Markets covered:<\/b> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/li>\n<li><b>Primary research:<\/b> Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research<\/li>\n<li><b>Epidemiology:<\/b> Diagnosed prevalent and drug-treated cases of <abbr title=\"immunoglobulin A\">IgA<\/abbr> nephropathy by country and age group<\/li>\n<li><strong>Drug treatments<\/strong><b>:<\/b> Coverage of key current and late-phase emerging therapies<\/li>\n<li><strong>Market forecast features<\/strong><b>:<\/b> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"immunoglobulin A\">IgA<\/abbr> nephropathy therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-497055","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/497055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=497055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}